ISSN 1674-3865  CN 21-1569/R
主管:国家卫生和计划生育委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

Chinese Pediatrics of Integrated Traditional and Western Medicine ›› 2025, Vol. 17 ›› Issue (5): 418-423.doi: 10.20274/j.cnki.issn.1674-3865.2025.05.010

Previous Articles     Next Articles

Cost-effectiveness analysis of traditional Chinese medicine and western medicine in the treatment of influenza in children

Wei SHAO1, Xifan MEI1, Feng WANG1, Fei YU1, Sunjun YIN2, Dan HAN3()   

  1. 1.Liaoning Vocational College of Medicine, Liaoning Institute of Basic Medical Sciences, Shenyang 110101, China
    2.The 920th Hospital of the Joint Logistic Support Force of PLA, Kunming 650032, China
    3.Naval Medical University, Shanghai 200433, China
  • Received:2025-03-05 Revised:2025-05-06 Published:2025-10-25 Online:2025-10-25
  • Contact: Dan HAN E-mail:handanxuan@163.com
  • Supported by:
    Shenyang Philosophy and Social Science Project(SYSK2024-01-130)

Abstract:

Objective To compare the cost-effectiveness of Xiaoer Feire Kechuan granules(XFK)with that of oseltamivir phosphate granules in the treatment of pediatric influenza to evaluate their economic value. Methods A decision tree model was developed from the perspective of the healthcare system to conduct a cost-effectiveness analysis. Univariate and probabilistic sensitivity analyses were performed to evaluate how parameter variations influenced the study outcomes. Results The incremental cost-effectiveness ratio(ICER) of XFK compared to oseltamivir phosphate granules was ¥96.8. The probabilistic sensitivity analysis results showed that over a 5-day treatment cycle, when the willingness-to-pay(WTP) exceeded ¥260, XFK became the more cost-effective option. Univariate sensitivity analysis indicated that the price of oseltamivir phosphate granules was the most sensitive factor among all the factors of ICER. Conclusion When the willingness-to-pay is over ¥260, XFK demonstrates a cost-effective advantage in the treatment of pediatric influenza.

Key words: Influenza, Xiaoer Feire Kechuan granules, Oseltamivir phosphate granules, Cost-effectiveness analysis, Child

CLC Number: